Table 5.
Anticoagulant Use by Renal Function Among Nursing Home Residents With Atrial Fibrillation
| No Diagnosis of Renal Insufficiency | Chronic Renal Insufficiencya | End‐Stage Renal Diseaseb | On Dialysisc | |
|---|---|---|---|---|
| December 31, 2016 | ||||
| n | 18 606 | 10 956 | 7014 | 1211 |
| Treated, % | 47.8 | 48.5 | 47.1 | 44.2 |
| Warfarin, % | 24.0 | 24.2 | 25.8 | 33.1 |
| Low‐dose DOAC, % | 10.5 | 12.9 | 12.8 | 7.7 |
| Standard‐dose DOAC, % | 13.4 | 11.4 | 8.4 | 3.4 |
| December 31, 2011 | ||||
| n | 19 319 | 9116 | 4713 | 811 |
| Treated, % | 43.1 | 42.8 | 38.5 | 39.7 |
| Warfarin, % | 40.0 | 39.8 | 36.1 | 39.7 |
| Low‐dose DOAC, % | 0.8 | 1.4 | 1.3 | 0.0 |
| Standard‐dose DOAC, % | 2.2 | 1.6 | 1.1 | 0.0 |
DOAC indicates direct‐acting oral anticoagulant.
Identified from in‐patient diagnoses. Corresponds to an estimated glomerular filtration rate <60 mL/min. Residents with evidence of more severe disease (end‐stage renal disease or on dialysis) were assigned to the more severe category.
Identified from the most recent MDS 3.0 assessment (item I1500: end‐stage renal disease). Residents with evidence of more severe disease (on dialysis) were assigned to the more severe category.
Identified from the most recent MDS 3.0 assessment (item O0100J2) which indicates whether the resident has received dialysis within the past 14 days while a resident of the nursing facility.